Literature DB >> 204536

Inhibition of VIP-stimulated intestinal secretion and cyclic AMP production by somatostatin in the rat.

R F Carter, K N Bitar, A M Zfass, G M Makhlouf.   

Abstract

The effect of somatostatin on colonic secretion induced by 10(-8) M vasoactive intestinal peptide (VIP), 10(-2) M theophylline, and 2 X 10(-3) M dibutyryl cyclic AMP was studied in muscle-stripped everted open rat colon sacs. The secretory response to VIP, measured as the decrease in net absorptive flow rate (microliters 30 min-1 mg-1 of dry weight), was maximal and equalled the responses to theophylline or dibutyryl cyclic AMP. Somatostatin (10(-5) M) blocked completely the secretory response to VIP but only partially the secretory response to theophylline or dibutyryl cyclic AMP. This difference in the extent of inhibition suggested that somatostatin exerted an inhibitory effect both before and after the point of generation of intracellular cyclic AMP. In order to test the hypothesis that one component of the action of somatostatin involved inhibition of the production of cyclic AMP, measurements of this nucleotide were made in isolated rat colon cells. Control levels of cyclic AMP measured by radioimmunoassay (12.6 +/- 1.6 pmoles per 10(6) cells) were not affected by 10(-5) M somatostatin. VIP (5 X 10(-8) M) increased cyclic AMP levels 2-fold (P less than 0.01) and this increase was blocked by somatostatin. The results indicated that somatostatin inhibits colonic secretion by exerting effects at two sites: one site lies at, and another beyond, the point of generation of intracellular cyclic AMP.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 204536

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  17 in total

1.  Neuropeptide Y antagonises secretagogue evoked chloride transport in rat jejunal epithelium.

Authors:  H M Cox; A W Cuthbert
Journal:  Pflugers Arch       Date:  1988-11       Impact factor: 3.657

2.  Structure-activity relationships of somatostatin analogs in the rabbit ileum and the rat colon.

Authors:  L E Rosenthal; D J Yamashiro; J Rivier; W Vale; M Brown; K Dharmsathaphorn
Journal:  J Clin Invest       Date:  1983-04       Impact factor: 14.808

Review 3.  Vasoactive intestinal peptide.

Authors:  S I Said
Journal:  J Endocrinol Invest       Date:  1986-04       Impact factor: 4.256

4.  In vivo and in vitro efficacy of octreotide for treatment of enteric cryptosporidiosis.

Authors:  A Guarino; R Berni Canani; M I Spagnuolo; M Bisceglia; M C Boccia; A Rubino
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

5.  Effect of somatostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera.

Authors:  A Ruskoné; E René; J A Chayvialle; N Bonin; F Pignal; M Kremer; S Bonfils; J C Rambaud
Journal:  Dig Dis Sci       Date:  1982-05       Impact factor: 3.199

6.  Somatostatin in human enteric nerves. Distribution and characterization.

Authors:  J R Keast; J B Furness; M Costa
Journal:  Cell Tissue Res       Date:  1984       Impact factor: 5.249

Review 7.  Antidiarrheal therapy. Prospects for new agents.

Authors:  R N Fedorak; M Field
Journal:  Dig Dis Sci       Date:  1987-02       Impact factor: 3.199

8.  Effect of somatostatin analog on water and electrolyte transport and transit time in human small bowel.

Authors:  M I Dueno; J C Bai; W C Santangelo; G J Krejs
Journal:  Dig Dis Sci       Date:  1987-10       Impact factor: 3.199

9.  Intestinal filtration as a consequence of increased mucosal hydraulic permeability. A new concept for laxative action.

Authors:  R Wanitschke
Journal:  Klin Wochenschr       Date:  1980-03-17

10.  Expression of calcitonin and somatostatin peptide and mRNA in medullary thyroid carcinoma.

Authors:  E Neonakis; G A Thomas; H G Davies; M H Wheeler; E D Williams
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.